ASPREE: Aspirin in Reducing Events in Elderly
Aspirin may help older people to live well for longer by delaying the onset of illnesses. In fact, previous studies have shown that low dose aspirin:
- Reduces the risk of heart attack, stroke and vascular events in middle aged people
- May help to prevent cognitive decline and forms of cancer such as bowel cancer
However, aspirin is known to have adverse-effects, such as bleeding, that may offset its benefits. Before doctors can know for sure if aspirin is helpful in prolonging a healthy life in older people, the benefits must be weighed against the risks.
The purpose of the ASPirin in Reducing Events in the Elderly (ASPREE) study, is to determine whether the potential benefits of aspirin outweigh the risks for people over age 65.
The ASPREE study:
- Is a randomized, double-blind placebo controlled study
- Involves both males and females, 65 years and older
Participants are randomly assigned to take either a low-dose aspirin tablet (100mg) or a placebo tablet (dummy pill) for a period of 5 years.
Annual follow-up visits will involve a number of health, clinical and other measurements. Any abnormalities will be reported to the participant’s doctor for further assessment.
The study will recruit approximately 19,000 healthy participants through regional centers (in Australia and the United States), which includes the Palo Alto Medical Foundation (PAMF)
The ASPREE study has completed enrollment of Non-Hispanic White/Caucasian patients and is currently open to enrollment for individuals from diverse populations.